Rat Model Market by Model Type (Outbred, Inbred, Knockout), Technology (CRISPR, Micro Injection), Therapeutic Area (Neurology, Oncology), Service (Breeding, Cryopreservation), Care Products (Cages, Feed, Bedding) & End User -Global Forecast to 2021
The rat model market is projected to reach USD 588.9 million by 2021 from USD 387.7 million in 2016, growing at a CAGR of 8.7% during the forecast period.
Continuous support in the form of investments and grants, and personalized medicine fueling the demand for personalized humanized rat models are some of the factors driving the growth of the rat model market. In addition to this, increase in R&D activities in pharmaceutical industries is further stimulating the market growth. However, increased benefits of cryopreservation and regulations & laws formulated for ethical use of animals in research are restraining the growth of the market to a certain extent.
The global rat model market is segmented on the basis of model type, service, technology, therapeutic area, end user, care product, and region. In 2016, North America is expected to account for the largest share of the global rat model market, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). Asia-Pacific is projected to have the highest growth rate during the forecast period. Factors such as less stringent regulations on the use of animal models for research in the region, international alliances for R&D activities in China, growth in regenerative medicine, biomedical, and medical research in Japan, growing presence of global players, development of bioclusters to boost biotechnology industry in India, ongoing biomedical research activities in Australia, and rising pharmaceutical and biotechnology R&D activities are likely to propel the market in the Asia-Pacific region.
The market witnesses high competitive intensity, as there are several big and many small firms with similar product offerings. These companies adopt various strategies (expansions; new product launches; collaborations/agreement/partnerships/alliance, funding; licensing, contract, acquisitions, and expansions) to increase their market shares and establish a strong foothold in the global market.
In-depth interviews were conducted with CEOs, Sales and Marketing Directors, other innovation and technology directors, and executives from various key organizations operating in the rat model market place.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps firms to garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
Continuous support in the form of investments and grants, and personalized medicine fueling the demand for personalized humanized rat models are some of the factors driving the growth of the rat model market. In addition to this, increase in R&D activities in pharmaceutical industries is further stimulating the market growth. However, increased benefits of cryopreservation and regulations & laws formulated for ethical use of animals in research are restraining the growth of the market to a certain extent.
The global rat model market is segmented on the basis of model type, service, technology, therapeutic area, end user, care product, and region. In 2016, North America is expected to account for the largest share of the global rat model market, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). Asia-Pacific is projected to have the highest growth rate during the forecast period. Factors such as less stringent regulations on the use of animal models for research in the region, international alliances for R&D activities in China, growth in regenerative medicine, biomedical, and medical research in Japan, growing presence of global players, development of bioclusters to boost biotechnology industry in India, ongoing biomedical research activities in Australia, and rising pharmaceutical and biotechnology R&D activities are likely to propel the market in the Asia-Pacific region.
The market witnesses high competitive intensity, as there are several big and many small firms with similar product offerings. These companies adopt various strategies (expansions; new product launches; collaborations/agreement/partnerships/alliance, funding; licensing, contract, acquisitions, and expansions) to increase their market shares and establish a strong foothold in the global market.
In-depth interviews were conducted with CEOs, Sales and Marketing Directors, other innovation and technology directors, and executives from various key organizations operating in the rat model market place.
- By Company Type: Tier 1: 50%, Tier 2: 42%, Tier 3: 8%
- By Designation: Director Level: 58%, C-level: 25%, Others: 17%
- By Region: North America: 46%, Europe: 31%, APAC: 15%, RoW: 8%
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps firms to garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the products and services offered by top players in the rat model market. The report analyzes the rat model market by model type, service, technology, therapeutic area, end user, care product, and region
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the rat model market
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for rat model across various regions
- Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the rat model market
- Competitive Assessment: In-depth assessment of market shares, strategies, products, and distribution networks of the leading players in the rat model market
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH METHODOLOGY
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY
2.2.1 SECONDARY RESEARCH
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY RESEARCH
2.2.2.1 Key data from primary sources
2.2.2.2 Key Insights from primary sources
2.2.2.3 Key industry insights
2.3 MARKET SIZE ESTIMATION METHODOLOGY
2.4 MARKET FORECAST METHODOLOGY
2.5 MARKET DATA VALIDATION AND TRIANGULATION
2.6 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
3.1 INTRODUCTION
3.2 CONCLUSION
4 PREMIUM INSIGHTS
4.1 RAT MODEL MARKET OVERVIEW
4.2 REGIONAL ANALYSIS: GLOBAL RAT CARE PRODUCT MARKET, BY TYPE
4.3 GLOBAL RAT MODEL MARKET, BY THERAPEUTIC AREA, 2016 & 2021
4.4 REGIONAL SNAPSHOT OF THE GLOBAL RAT MODEL MARKET
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Advancements in gene editing tools set to augment the demand for rat models
5.2.1.2 Advantages offered by rats over mice
5.2.1.3 Continuous support in the form of investments and grants
5.2.1.4 Increased demand for personalized humanized rat models due to growing consumption of personalized medicines
5.2.1.5 Increase in R&D activities carried out by pharmaceutical and biotechnology companies
5.2.2 RESTRAINTS
5.2.2.1 Regulations & laws formulated for ethical use of animals
5.2.2.1.1 The Animal Welfare Act (AWA)
5.2.2.1.2 Public health service policy (PHS) on humane care and use of laboratory animals
5.2.2.2 Increased benefits offered by cryopreservation
5.2.3 OPPORTUNITIES
5.2.3.1 Increased production of monoclonal antibodies
5.2.3.2 Rising demand of humanized rat models
5.2.4 CHALLENGES
5.2.4.1 Advancements in zebrafish model development
5.2.4.2 Development of methods alternative to animal testing
6 CLINICAL TRIALS & RESEARCH STUDIES ASSESSMENT
6.1 INTRODUCTION
6.2 CLINICAL TRIALS
6.3 RESEARCH STUDIES
7 GLOBAL RAT MODEL MARKET, BY MODEL TYPE
7.1 INTRODUCTION
7.2 OUTBRED RATS
7.3 INBRED RATS
7.4 KNOCKOUT/GENETICALLY ENGINEERED RATS
7.5 HYBRID/CONGENIC RATS
7.6 CONDITIONED/SURGICALLY MODIFIED RATS
7.7 IMMUNODEFICIENT RATS
8 GLOBAL RAT MODEL MARKET, BY SERVICE
8.1 INTRODUCTION
8.2 BREEDING
8.3 CRYOPRESERVATION
8.4 QUARANTINE
8.5 REDERIVATION
8.6 MODEL IN-LICENSING
8.7 GENETIC TESTING
8.8 OTHERS
8.8.1 SURGICAL SERVICES
8.8.2 LINE RESCUE SERVICES
8.8.3 IN VIVO PHARMACOLOGY SERVICES
9 GLOBAL RAT MODEL MARKET, BY TECHNOLOGY
9.1 INTRODUCTION
9.2 CRISPR
9.3 MICROINJECTION
9.4 EMBRYONIC STEM CELL INJECTION
9.5 NUCLEAR TRANSFER
9.6 OTHER TECHNOLOGIES
10 GLOBAL RAT MODEL MARKET, BY THERAPEUTIC AREA
10.1 INTRODUCTION
10.2 TOXICOLOGY
10.3 ONCOLOGY
10.3.1 NEW PRODUCT LAUNCHES FOR ONCOLOGY RESEARCH
10.3.2 CONTINUOUS GRANTS/FUNDS TO SUPPORT CANCER RESEARCH STUDIES
10.4 IMMUNOLOGY AND INFLAMMATION
10.5 NEUROLOGY
10.6 DIABETES
10.7 OTHERS
11 GLOBAL RAT MODEL MARKET, BY END USER
11.1 INTRODUCTION
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.3 ACADEMIC & RESEARCH INSTITUTIONS
11.4 CONTRACT RESEARCH ORGANIZATIONS (CRO)
12 GLOBAL RAT MODEL MARKET, BY CARE PRODUCT
12.1 INTRODUCTION
12.2 CAGES
12.3 FEED
12.4 BEDDING
12.5 OTHER CARE PRODUCTS
13 GLOBAL RAT MODEL MARKET, BY REGION
13.1 INTRODUCTION
13.2 NORTH AMERICA
13.2.1 U.S.
13.2.1.1 Growing biomedical research in the U.S.
13.2.1.2 Preclinical activities by CROs and pharmaceutical R&D
13.2.1.3 Continued and responsible use of animals ensured by animal care organizations
13.2.1.4 Development of biosimilars product boosting the demand for preclinical services
13.2.1.5 Monoclonal antibody production to augment the use of rat models
13.2.1.6 Partnership between CROs and pharmaceutical companies
13.2.2 CANADA
13.2.2.1 Growing stem cell research activities in Canada
13.2.2.2 Government support for development of protein drugs is expected to drive the rat model market
13.3 EUROPE
13.3.1 GERMANY
13.3.1.1 Launch of Pro-Test Deutschland
13.3.1.2 Flourishing biotechnology industry
13.3.2 U.K.
13.3.2.1 Investors demand strong statistics for animal studies in the U.K.
13.3.2.2 Increase in cell therapy preclinical research
13.3.3 FRANCE
13.3.3.1 Funding for Rare Disease Projects in France
13.3.4 RUSSIA
13.3.4.1 Growing biomedical industry in Russia
13.3.5 REST OF EUROPE
13.3.5.1 Growth in biotech and pharma sector of Italy
13.3.5.2 Growing investments in research by Sweden & Denmark
13.3.5.3 Focus on rare disease research projects
13.3.5.4 Growth in Biosimilars market to lead to increased preclinical activities
13.4 ASIA-PACIFIC
13.4.1 CHINA
13.4.1.1 International alliances for R&D activities in China
13.4.1.2 Initiatives to reduce longer approval times
13.4.1.3 Intellectual property (IP) breaches, a challenge for the China market
13.4.1.4 Mandatory animal testing for all pharmaceutical drugs and cosmetics in China
13.4.1.5 Increasing investments from government and private sectors in China’s life sciences sector
13.4.2 JAPAN
13.4.2.1 Growth in biomedical and medical research in Japan
13.4.2.2 Research in regenerative medicine
13.4.2.3 Focus on cancer research and treatment
13.4.3 INDIA
13.4.3.1 Growth of the pharmaceutical industry in India
13.4.3.2 Development of bio-clusters to boost India’s biotechnology
13.4.3.3 Growing presence of global players
13.4.3.4 Shift of outsourcing preclinical activities from India to European nations
13.4.3.5 Weak intellectual property environment in India
13.4.3.6 Limited infrastructural facilities in India, a major hindrance for growth of the rat model market
13.4.4 REST OF ASIA-PACIFIC
13.4.4.1 Ongoing Biomedical research activities in Australia to strengthen the market
13.4.4.2 Growth in translational and biomedical research in Singapore
13.4.4.3 Increase in animal research in Malaysia
13.4.4.4 Government support for strong academic and commercial R&D activities in Taiwan
13.4.4.5 Rising pharmaceutical and biotechnology R&D activities in Korea
13.5 REST OF THE WORLD
13.5.1.1 Pharmaceutical, biotechnology, and research industries in Brazil to drive market growth
13.5.1.2 Favorable business environment for pharmaceutical and biotechnology industries in Saudi Arabia and the UAE
13.5.1.3 Increasing investments in Mexico
14 COMPETITIVE LANDSCAPE
14.1 OVERVIEW
14.2 MARKET SHARE ANALYSIS
14.2.1 INTRODUCTION
14.2.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (U.S.)
14.2.3 ENVIGO (U.K.)
14.2.4 TACONIC BIOSCIENCES, INC. (U.S.)
14.3 COMPETITIVE SITUATION AND TRENDS
14.4 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
14.5 ACQUISITIONS
14.6 EXPANSIONS
14.7 NEW PRODUCT LAUNCHES
14.8 OTHER STRATEGIES
15 COMPANY PROFILES
(Overview, Products and Services, Financials, Strategy & Development)*
15.1 INTRODUCTION
15.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
15.3 TACONIC BIOSCIENCES, INC.
15.4 ENVIGO
15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS
15.6 JANVIER LABS
15.7 GENOWAY S.A.
15.8 BIOMERE
15.9 TRANSPOSAGEN BIOPHARMACEUTICALS, INC.
15.10 HORIZON DISCOVERY GROUP PLC
15.11 TRANSVIRAGEN, INC.
*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.
16 APPENDIX
16.1 DISCUSSION GUIDE
16.2 OTHER DEVELOPMENTS
16.2.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
16.2.2 TACONIC BIOSCIENCES, INC.
16.2.3 ENVIGO
16.2.4 LABORATORY CORPORATION OF AMERICA HOLDINGS
16.2.5 GENOWAY S.A.
16.2.6 HORIZON DISCOVERY GROUP PLC
16.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
16.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
16.5 AVAILABLE CUSTOMIZATIONS
16.6 RELATED REPORTS
16.7 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH METHODOLOGY
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY
2.2.1 SECONDARY RESEARCH
2.2.1.1 Key data from secondary sources
2.2.2 PRIMARY RESEARCH
2.2.2.1 Key data from primary sources
2.2.2.2 Key Insights from primary sources
2.2.2.3 Key industry insights
2.3 MARKET SIZE ESTIMATION METHODOLOGY
2.4 MARKET FORECAST METHODOLOGY
2.5 MARKET DATA VALIDATION AND TRIANGULATION
2.6 ASSUMPTIONS FOR THE STUDY
3 EXECUTIVE SUMMARY
3.1 INTRODUCTION
3.2 CONCLUSION
4 PREMIUM INSIGHTS
4.1 RAT MODEL MARKET OVERVIEW
4.2 REGIONAL ANALYSIS: GLOBAL RAT CARE PRODUCT MARKET, BY TYPE
4.3 GLOBAL RAT MODEL MARKET, BY THERAPEUTIC AREA, 2016 & 2021
4.4 REGIONAL SNAPSHOT OF THE GLOBAL RAT MODEL MARKET
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Advancements in gene editing tools set to augment the demand for rat models
5.2.1.2 Advantages offered by rats over mice
5.2.1.3 Continuous support in the form of investments and grants
5.2.1.4 Increased demand for personalized humanized rat models due to growing consumption of personalized medicines
5.2.1.5 Increase in R&D activities carried out by pharmaceutical and biotechnology companies
5.2.2 RESTRAINTS
5.2.2.1 Regulations & laws formulated for ethical use of animals
5.2.2.1.1 The Animal Welfare Act (AWA)
5.2.2.1.2 Public health service policy (PHS) on humane care and use of laboratory animals
5.2.2.2 Increased benefits offered by cryopreservation
5.2.3 OPPORTUNITIES
5.2.3.1 Increased production of monoclonal antibodies
5.2.3.2 Rising demand of humanized rat models
5.2.4 CHALLENGES
5.2.4.1 Advancements in zebrafish model development
5.2.4.2 Development of methods alternative to animal testing
6 CLINICAL TRIALS & RESEARCH STUDIES ASSESSMENT
6.1 INTRODUCTION
6.2 CLINICAL TRIALS
6.3 RESEARCH STUDIES
7 GLOBAL RAT MODEL MARKET, BY MODEL TYPE
7.1 INTRODUCTION
7.2 OUTBRED RATS
7.3 INBRED RATS
7.4 KNOCKOUT/GENETICALLY ENGINEERED RATS
7.5 HYBRID/CONGENIC RATS
7.6 CONDITIONED/SURGICALLY MODIFIED RATS
7.7 IMMUNODEFICIENT RATS
8 GLOBAL RAT MODEL MARKET, BY SERVICE
8.1 INTRODUCTION
8.2 BREEDING
8.3 CRYOPRESERVATION
8.4 QUARANTINE
8.5 REDERIVATION
8.6 MODEL IN-LICENSING
8.7 GENETIC TESTING
8.8 OTHERS
8.8.1 SURGICAL SERVICES
8.8.2 LINE RESCUE SERVICES
8.8.3 IN VIVO PHARMACOLOGY SERVICES
9 GLOBAL RAT MODEL MARKET, BY TECHNOLOGY
9.1 INTRODUCTION
9.2 CRISPR
9.3 MICROINJECTION
9.4 EMBRYONIC STEM CELL INJECTION
9.5 NUCLEAR TRANSFER
9.6 OTHER TECHNOLOGIES
10 GLOBAL RAT MODEL MARKET, BY THERAPEUTIC AREA
10.1 INTRODUCTION
10.2 TOXICOLOGY
10.3 ONCOLOGY
10.3.1 NEW PRODUCT LAUNCHES FOR ONCOLOGY RESEARCH
10.3.2 CONTINUOUS GRANTS/FUNDS TO SUPPORT CANCER RESEARCH STUDIES
10.4 IMMUNOLOGY AND INFLAMMATION
10.5 NEUROLOGY
10.6 DIABETES
10.7 OTHERS
11 GLOBAL RAT MODEL MARKET, BY END USER
11.1 INTRODUCTION
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
11.3 ACADEMIC & RESEARCH INSTITUTIONS
11.4 CONTRACT RESEARCH ORGANIZATIONS (CRO)
12 GLOBAL RAT MODEL MARKET, BY CARE PRODUCT
12.1 INTRODUCTION
12.2 CAGES
12.3 FEED
12.4 BEDDING
12.5 OTHER CARE PRODUCTS
13 GLOBAL RAT MODEL MARKET, BY REGION
13.1 INTRODUCTION
13.2 NORTH AMERICA
13.2.1 U.S.
13.2.1.1 Growing biomedical research in the U.S.
13.2.1.2 Preclinical activities by CROs and pharmaceutical R&D
13.2.1.3 Continued and responsible use of animals ensured by animal care organizations
13.2.1.4 Development of biosimilars product boosting the demand for preclinical services
13.2.1.5 Monoclonal antibody production to augment the use of rat models
13.2.1.6 Partnership between CROs and pharmaceutical companies
13.2.2 CANADA
13.2.2.1 Growing stem cell research activities in Canada
13.2.2.2 Government support for development of protein drugs is expected to drive the rat model market
13.3 EUROPE
13.3.1 GERMANY
13.3.1.1 Launch of Pro-Test Deutschland
13.3.1.2 Flourishing biotechnology industry
13.3.2 U.K.
13.3.2.1 Investors demand strong statistics for animal studies in the U.K.
13.3.2.2 Increase in cell therapy preclinical research
13.3.3 FRANCE
13.3.3.1 Funding for Rare Disease Projects in France
13.3.4 RUSSIA
13.3.4.1 Growing biomedical industry in Russia
13.3.5 REST OF EUROPE
13.3.5.1 Growth in biotech and pharma sector of Italy
13.3.5.2 Growing investments in research by Sweden & Denmark
13.3.5.3 Focus on rare disease research projects
13.3.5.4 Growth in Biosimilars market to lead to increased preclinical activities
13.4 ASIA-PACIFIC
13.4.1 CHINA
13.4.1.1 International alliances for R&D activities in China
13.4.1.2 Initiatives to reduce longer approval times
13.4.1.3 Intellectual property (IP) breaches, a challenge for the China market
13.4.1.4 Mandatory animal testing for all pharmaceutical drugs and cosmetics in China
13.4.1.5 Increasing investments from government and private sectors in China’s life sciences sector
13.4.2 JAPAN
13.4.2.1 Growth in biomedical and medical research in Japan
13.4.2.2 Research in regenerative medicine
13.4.2.3 Focus on cancer research and treatment
13.4.3 INDIA
13.4.3.1 Growth of the pharmaceutical industry in India
13.4.3.2 Development of bio-clusters to boost India’s biotechnology
13.4.3.3 Growing presence of global players
13.4.3.4 Shift of outsourcing preclinical activities from India to European nations
13.4.3.5 Weak intellectual property environment in India
13.4.3.6 Limited infrastructural facilities in India, a major hindrance for growth of the rat model market
13.4.4 REST OF ASIA-PACIFIC
13.4.4.1 Ongoing Biomedical research activities in Australia to strengthen the market
13.4.4.2 Growth in translational and biomedical research in Singapore
13.4.4.3 Increase in animal research in Malaysia
13.4.4.4 Government support for strong academic and commercial R&D activities in Taiwan
13.4.4.5 Rising pharmaceutical and biotechnology R&D activities in Korea
13.5 REST OF THE WORLD
13.5.1.1 Pharmaceutical, biotechnology, and research industries in Brazil to drive market growth
13.5.1.2 Favorable business environment for pharmaceutical and biotechnology industries in Saudi Arabia and the UAE
13.5.1.3 Increasing investments in Mexico
14 COMPETITIVE LANDSCAPE
14.1 OVERVIEW
14.2 MARKET SHARE ANALYSIS
14.2.1 INTRODUCTION
14.2.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (U.S.)
14.2.3 ENVIGO (U.K.)
14.2.4 TACONIC BIOSCIENCES, INC. (U.S.)
14.3 COMPETITIVE SITUATION AND TRENDS
14.4 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS
14.5 ACQUISITIONS
14.6 EXPANSIONS
14.7 NEW PRODUCT LAUNCHES
14.8 OTHER STRATEGIES
15 COMPANY PROFILES
(Overview, Products and Services, Financials, Strategy & Development)*
15.1 INTRODUCTION
15.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
15.3 TACONIC BIOSCIENCES, INC.
15.4 ENVIGO
15.5 LABORATORY CORPORATION OF AMERICA HOLDINGS
15.6 JANVIER LABS
15.7 GENOWAY S.A.
15.8 BIOMERE
15.9 TRANSPOSAGEN BIOPHARMACEUTICALS, INC.
15.10 HORIZON DISCOVERY GROUP PLC
15.11 TRANSVIRAGEN, INC.
*Details on Overview, Products and Services, Financials, Strategy & Development might not be Captured in case of Unlisted Companies.
16 APPENDIX
16.1 DISCUSSION GUIDE
16.2 OTHER DEVELOPMENTS
16.2.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
16.2.2 TACONIC BIOSCIENCES, INC.
16.2.3 ENVIGO
16.2.4 LABORATORY CORPORATION OF AMERICA HOLDINGS
16.2.5 GENOWAY S.A.
16.2.6 HORIZON DISCOVERY GROUP PLC
16.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
16.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
16.5 AVAILABLE CUSTOMIZATIONS
16.6 RELATED REPORTS
16.7 AUTHOR DETAILS
LIST OF TABLES
Table 1 INDICATIVE LIST OF CLINICAL TRIALS CONDUCTED ON RAT MODELS
Table 2 INDICATIVE LIST OF RESEARCH STUDIES CONDUCTED ON RAT MODELS
Table 3 GLOBAL RAT MODEL MARKET, BY MODEL TYPE, 2014-2021 (USD MILLION)
Table 4 RAT MODEL MARKET FOR OUTBRED RATS, BY REGION, 2014-2021 (USD THOUSAND)
Table 5 RAT MODEL MARKET FOR INBRED RATS, BY REGION, 2014-2021 (USD THOUSAND)
Table 6 RAT MODEL MARKET FOR KNOCKOUT/GENETICALLY ENGINEERED RATS, BY REGION, 2014-2021 (USD THOUSAND)
Table 7 RAT MODEL MARKET FOR HYBRID/CONGENIC RATS, BY REGION, 2013-2021 (USD THOUSAND)
Table 8 RAT MODEL MARKET FOR CONDITIONED/SURGICALLY MODIFIED RATS, BY REGION, 2013-2021 (USD THOUSAND)
Table 9 RAT MODEL MARKET FOR IMMUNODEFICIENT RATS, BY REGION, 2013-2021 (USD THOUSAND)
Table 10 GLOBAL RAT MODEL MARKET, BY SERVICE, 2014-2021 (USD MILLION)
Table 11 RAT MODEL MARKET FOR BREEDING, BY REGION, 2014-2021 (USD THOUSAND)
Table 12 RAT MODEL MARKET FOR CRYOPRESERVATION, BY REGION, 2014-2021 (USD THOUSAND)
Table 13 RAT MODEL MARKET FOR QUARANTINE, BY REGION, 2014-2021 (USD THOUSAND)
Table 14 RAT MODEL MARKET FOR REDERIVATION, BY REGION, 2014-2021 (USD THOUSAND)
Table 15 RAT MODEL MARKET FOR MODEL IN-LICENSING, BY REGION, 2014-2021 (USD THOUSAND)
Table 16 RAT MODEL MARKET FOR GENETIC TESTING, BY REGION, 2014-2021 (USD THOUSAND)
Table 17 RAT MODEL MARKET FOR OTHERS, BY REGION, 2014-2021 (USD THOUSAND)
Table 18 GLOBAL RAT MODEL MARKET, BY TECHNOLOGY, 2014-2021 (USD MILLION)
Table 19 RAT MODEL MARKET FOR CRISPR, BY REGION, 2014-2021 (USD THOUSAND)
Table 20 RAT MODEL MARKET FOR MICROINJECTION, BY REGION, 2014-2021 (USD THOUSAND)
Table 21 RAT MODEL MARKET FOR EMBRYONIC STEM CELL INJECTION, BY REGION, 2014-2021 (USD THOUSAND)
Table 22 RAT MODEL MARKET FOR NUCLEAR TRANSFER, BY REGION, 2014-2021 (USD THOUSAND)
Table 23 RAT MODEL MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2014-2021 (USD THOUSAND)
Table 24 GLOBAL RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014-2021 (USD MILLION)
Table 25 RAT MODEL MARKET IN TOXICOLOGY, BY REGION, 2014-2021 (USD THOUSAND)
Table 26 LIST OF CANCER RESEARCH STUDIES USING RAT MODELS
Table 27 RAT MODEL MARKET IN ONCOLOGY, BY REGION, 2013-2021 (USD THOUSAND)
Table 28 RAT MODEL MARKET IN IMMUNOLOGY AND INFLAMMATION, BY REGION, 2014-2021 (USD THOUSAND)
Table 29 INDICATIVE LIST OF NEUROLOGICAL RESEARCH STUDIES USING RAT MODEL
Table 30 RAT MODEL MARKET IN NEUROLOGY, BY REGION, 2014-2021 (USD THOUSAND)
Table 31 RAT MODEL MARKET IN DIABETES, BY REGION, 2014-2021 (USD THOUSAND)
Table 32 RAT MODEL MARKET IN OTHERS, BY REGION, 2014-2021 (USD THOUSAND)
Table 33 GLOBAL RAT MODEL MARKET, BY END USER, 2014-2021 (USD MILLION)
Table 34 RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2014-2021 (USD THOUSAND)
Table 35 RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2014-2021 (USD THOUSAND)
Table 36 RAT MODEL MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2014-2021 (USD THOUSAND)
Table 37 GLOBAL RAT CARE PRODUCT MARKET, BY TYPE, 2014-2021 (USD THOUSAND)
Table 38 RAT CARE PRODUCT MARKET FOR CAGES, BY REGION, 2014-2021 (USD THOUSAND)
Table 39 RAT CARE PRODUCT MARKET FOR FEED, BY REGION, 2014-2021 (USD THOUSAND)
Table 40 RAT CARE PRODUCT MARKET FOR BEDDING, BY REGION, 2014-2021 (USD THOUSAND)
Table 41 RAT CARE PRODUCT MARKET FOR OTHER CARE PRODUCTS, BY REGION, 2014-2021 (USD THOUSAND)
Table 42 RAT MODEL MARKET, BY REGION, 2014–2021 (USD MILLION)
Table 43 NORTH AMERICA: RAT MODEL MARKET, BY COUNTRY, 2014–2021 (USD MILLION)
Table 44 NORTH AMERICA: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD MILLION)
Table 45 NORTH AMERICA: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 46 NORTH AMERICA: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 47 NORTH AMERICA: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 48 NORTH AMERICA: RAT MODEL MARKET, BY END USER, 2014–2021 (USD MILLION)
Table 49 NORTH AMERICA: RAT CARE PRODUCT MARKET, BY CARE PRODUCT, 2014–2021 (USD THOUSAND)
Table 50 NIH FUNDING FOR PROJECTS RELATED TO ANIMAL MODELS
Table 51 ASSOCIATIONS DIRECTLY RELATED TO THE ANIMAL MODEL MARKET
Table 52 ASSOCIATIONS INDIRECTLY RELATED TO THE ANIMAL MODEL MARKET
Table 53 U.S.: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD MILLION)
Table 54 U.S.: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD MILLION)
Table 55 U.S.: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD MILLION)
Table 56 U.S.: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 57 U.S.: RAT MODEL MARKET, BY END USER, 2014–2021 (USD MILLION)
Table 58 CANADA: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 59 CANADA: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 60 CANADA: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 61 CANADA: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 62 CANADA: RAT MODEL MARKET, BY END USER, 2014–2021 (USD THOUSAND)
Table 63 EUROPE: RAT MODEL MARKET, BY COUNTRY, 2014–2021 (USD THOUSAND)
Table 64 EUROPE: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD MILLION)
Table 65 EUROPE: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 66 EUROPE: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 67 EUROPE: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 68 EUROPE: RAT MODEL MARKET, BY END USER, 2014–2021 (USD MILLION)
Table 69 EUROPE: RAT CARE PRODUCT MARKET, BY CARE PRODUCT, 2014–2021 (USD THOUSAND)
Table 70 GERMANY: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 71 GERMANY: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 72 GERMANY: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 73 GERMANY: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 74 GERMANY: RAT MODEL MARKET, BY END USER, 2014–2021 (USD MILLION)
Table 75 U.K.: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 76 U.K.: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 77 U.K.: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 78 U.K.: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 79 U.K.: RAT MODEL MARKET, BY END USER, 2014–2021 (USD MILLION)
Table 80 FRANCE: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 81 FRANCE: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 82 FRANCE: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 83 FRANCE: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 84 FRANCE: RAT MODEL MARKET, BY END USER, 2014–2021 (USD THOUSAND)
Table 85 RUSSIA: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 86 RUSSIA: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 87 RUSSIA: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 88 RUSSIA: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 89 RUSSIA: RAT MODEL MARKET, BY END USER, 2014–2021 (USD THOUSAND)
Table 90 ROE: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 91 ROE: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 92 ROE: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 93 ROE: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 94 ROE: RAT MODEL MARKET, BY END USER, 2014–2021 (USD THOUSAND)
Table 95 ASIA-PACIFIC: RAT MODEL MARKET, BY COUNTRY, 2014–2021 (USD MILLION)
Table 96 ASIA-PACIFIC: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 97 ASIA-PACIFIC: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 98 ASIA-PACIFIC: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 99 ASIA-PACIFIC: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 100 ASIA-PACIFIC: RAT MODEL MARKET, BY END USER, 2014–2021 (USD MILLION)
Table 101 ASIA-PACIFIC: RAT CARE PRODUCTS MARKET, BY CARE PRODUCT, 2014–2021 (USD THOUSAND)
Table 102 CHINA: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 103 CHINA: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 104 CHINA: RAT MODEL MARKET SIZE, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 105 CHINA: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 106 CHINA: RAT MODEL MARKET, BY END USER, 2014–2021 (USD MILLION)
Table 107 JAPAN: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 108 JAPAN: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 109 JAPAN.: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 110 JAPAN: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 111 JAPAN: RAT MODEL MARKET, BY END USER, 2014–2021 (USD THOUSAND)
Table 112 INDIA: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 113 INDIA: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 114 INDIA: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 115 INDIA: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 116 INDIA: RAT MODEL MARKET, BY END USER, 2014–2021 (USD THOUSAND)
Table 117 REST OF APAC: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 118 REST OF APAC: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 119 REST OF APAC: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 120 REST OF APAC: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 121 REST OF APAC: RAT MODEL MARKET, BY END USER, 2014–2021 (USD THOUSAND)
Table 122 ROW: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 123 ROW: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 124 ROW: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 125 ROW: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 126 ROW: RAT MODEL MARKET, BY END USER, 2014–2021 (USD THOUSAND)
Table 127 ROW: RAT CARE PRODUCT MARKET, BY CARE PRODUCT, 2014–2021 (USD THOUSAND)
Table 128 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, 2013–2016
Table 129 ACQUISITIONS, 2013–2016
Table 130 EXPANSIONS, 2013–2016
Table 131 NEW PRODUCT LAUNCHES, 2013–2016
Table 132 OTHER STRATEGIES, 2013–2016
Table 1 INDICATIVE LIST OF CLINICAL TRIALS CONDUCTED ON RAT MODELS
Table 2 INDICATIVE LIST OF RESEARCH STUDIES CONDUCTED ON RAT MODELS
Table 3 GLOBAL RAT MODEL MARKET, BY MODEL TYPE, 2014-2021 (USD MILLION)
Table 4 RAT MODEL MARKET FOR OUTBRED RATS, BY REGION, 2014-2021 (USD THOUSAND)
Table 5 RAT MODEL MARKET FOR INBRED RATS, BY REGION, 2014-2021 (USD THOUSAND)
Table 6 RAT MODEL MARKET FOR KNOCKOUT/GENETICALLY ENGINEERED RATS, BY REGION, 2014-2021 (USD THOUSAND)
Table 7 RAT MODEL MARKET FOR HYBRID/CONGENIC RATS, BY REGION, 2013-2021 (USD THOUSAND)
Table 8 RAT MODEL MARKET FOR CONDITIONED/SURGICALLY MODIFIED RATS, BY REGION, 2013-2021 (USD THOUSAND)
Table 9 RAT MODEL MARKET FOR IMMUNODEFICIENT RATS, BY REGION, 2013-2021 (USD THOUSAND)
Table 10 GLOBAL RAT MODEL MARKET, BY SERVICE, 2014-2021 (USD MILLION)
Table 11 RAT MODEL MARKET FOR BREEDING, BY REGION, 2014-2021 (USD THOUSAND)
Table 12 RAT MODEL MARKET FOR CRYOPRESERVATION, BY REGION, 2014-2021 (USD THOUSAND)
Table 13 RAT MODEL MARKET FOR QUARANTINE, BY REGION, 2014-2021 (USD THOUSAND)
Table 14 RAT MODEL MARKET FOR REDERIVATION, BY REGION, 2014-2021 (USD THOUSAND)
Table 15 RAT MODEL MARKET FOR MODEL IN-LICENSING, BY REGION, 2014-2021 (USD THOUSAND)
Table 16 RAT MODEL MARKET FOR GENETIC TESTING, BY REGION, 2014-2021 (USD THOUSAND)
Table 17 RAT MODEL MARKET FOR OTHERS, BY REGION, 2014-2021 (USD THOUSAND)
Table 18 GLOBAL RAT MODEL MARKET, BY TECHNOLOGY, 2014-2021 (USD MILLION)
Table 19 RAT MODEL MARKET FOR CRISPR, BY REGION, 2014-2021 (USD THOUSAND)
Table 20 RAT MODEL MARKET FOR MICROINJECTION, BY REGION, 2014-2021 (USD THOUSAND)
Table 21 RAT MODEL MARKET FOR EMBRYONIC STEM CELL INJECTION, BY REGION, 2014-2021 (USD THOUSAND)
Table 22 RAT MODEL MARKET FOR NUCLEAR TRANSFER, BY REGION, 2014-2021 (USD THOUSAND)
Table 23 RAT MODEL MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2014-2021 (USD THOUSAND)
Table 24 GLOBAL RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014-2021 (USD MILLION)
Table 25 RAT MODEL MARKET IN TOXICOLOGY, BY REGION, 2014-2021 (USD THOUSAND)
Table 26 LIST OF CANCER RESEARCH STUDIES USING RAT MODELS
Table 27 RAT MODEL MARKET IN ONCOLOGY, BY REGION, 2013-2021 (USD THOUSAND)
Table 28 RAT MODEL MARKET IN IMMUNOLOGY AND INFLAMMATION, BY REGION, 2014-2021 (USD THOUSAND)
Table 29 INDICATIVE LIST OF NEUROLOGICAL RESEARCH STUDIES USING RAT MODEL
Table 30 RAT MODEL MARKET IN NEUROLOGY, BY REGION, 2014-2021 (USD THOUSAND)
Table 31 RAT MODEL MARKET IN DIABETES, BY REGION, 2014-2021 (USD THOUSAND)
Table 32 RAT MODEL MARKET IN OTHERS, BY REGION, 2014-2021 (USD THOUSAND)
Table 33 GLOBAL RAT MODEL MARKET, BY END USER, 2014-2021 (USD MILLION)
Table 34 RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2014-2021 (USD THOUSAND)
Table 35 RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2014-2021 (USD THOUSAND)
Table 36 RAT MODEL MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2014-2021 (USD THOUSAND)
Table 37 GLOBAL RAT CARE PRODUCT MARKET, BY TYPE, 2014-2021 (USD THOUSAND)
Table 38 RAT CARE PRODUCT MARKET FOR CAGES, BY REGION, 2014-2021 (USD THOUSAND)
Table 39 RAT CARE PRODUCT MARKET FOR FEED, BY REGION, 2014-2021 (USD THOUSAND)
Table 40 RAT CARE PRODUCT MARKET FOR BEDDING, BY REGION, 2014-2021 (USD THOUSAND)
Table 41 RAT CARE PRODUCT MARKET FOR OTHER CARE PRODUCTS, BY REGION, 2014-2021 (USD THOUSAND)
Table 42 RAT MODEL MARKET, BY REGION, 2014–2021 (USD MILLION)
Table 43 NORTH AMERICA: RAT MODEL MARKET, BY COUNTRY, 2014–2021 (USD MILLION)
Table 44 NORTH AMERICA: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD MILLION)
Table 45 NORTH AMERICA: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 46 NORTH AMERICA: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 47 NORTH AMERICA: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 48 NORTH AMERICA: RAT MODEL MARKET, BY END USER, 2014–2021 (USD MILLION)
Table 49 NORTH AMERICA: RAT CARE PRODUCT MARKET, BY CARE PRODUCT, 2014–2021 (USD THOUSAND)
Table 50 NIH FUNDING FOR PROJECTS RELATED TO ANIMAL MODELS
Table 51 ASSOCIATIONS DIRECTLY RELATED TO THE ANIMAL MODEL MARKET
Table 52 ASSOCIATIONS INDIRECTLY RELATED TO THE ANIMAL MODEL MARKET
Table 53 U.S.: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD MILLION)
Table 54 U.S.: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD MILLION)
Table 55 U.S.: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD MILLION)
Table 56 U.S.: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 57 U.S.: RAT MODEL MARKET, BY END USER, 2014–2021 (USD MILLION)
Table 58 CANADA: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 59 CANADA: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 60 CANADA: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 61 CANADA: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 62 CANADA: RAT MODEL MARKET, BY END USER, 2014–2021 (USD THOUSAND)
Table 63 EUROPE: RAT MODEL MARKET, BY COUNTRY, 2014–2021 (USD THOUSAND)
Table 64 EUROPE: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD MILLION)
Table 65 EUROPE: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 66 EUROPE: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 67 EUROPE: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 68 EUROPE: RAT MODEL MARKET, BY END USER, 2014–2021 (USD MILLION)
Table 69 EUROPE: RAT CARE PRODUCT MARKET, BY CARE PRODUCT, 2014–2021 (USD THOUSAND)
Table 70 GERMANY: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 71 GERMANY: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 72 GERMANY: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 73 GERMANY: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 74 GERMANY: RAT MODEL MARKET, BY END USER, 2014–2021 (USD MILLION)
Table 75 U.K.: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 76 U.K.: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 77 U.K.: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 78 U.K.: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 79 U.K.: RAT MODEL MARKET, BY END USER, 2014–2021 (USD MILLION)
Table 80 FRANCE: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 81 FRANCE: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 82 FRANCE: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 83 FRANCE: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 84 FRANCE: RAT MODEL MARKET, BY END USER, 2014–2021 (USD THOUSAND)
Table 85 RUSSIA: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 86 RUSSIA: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 87 RUSSIA: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 88 RUSSIA: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 89 RUSSIA: RAT MODEL MARKET, BY END USER, 2014–2021 (USD THOUSAND)
Table 90 ROE: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 91 ROE: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 92 ROE: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 93 ROE: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 94 ROE: RAT MODEL MARKET, BY END USER, 2014–2021 (USD THOUSAND)
Table 95 ASIA-PACIFIC: RAT MODEL MARKET, BY COUNTRY, 2014–2021 (USD MILLION)
Table 96 ASIA-PACIFIC: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 97 ASIA-PACIFIC: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 98 ASIA-PACIFIC: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 99 ASIA-PACIFIC: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 100 ASIA-PACIFIC: RAT MODEL MARKET, BY END USER, 2014–2021 (USD MILLION)
Table 101 ASIA-PACIFIC: RAT CARE PRODUCTS MARKET, BY CARE PRODUCT, 2014–2021 (USD THOUSAND)
Table 102 CHINA: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 103 CHINA: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 104 CHINA: RAT MODEL MARKET SIZE, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 105 CHINA: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 106 CHINA: RAT MODEL MARKET, BY END USER, 2014–2021 (USD MILLION)
Table 107 JAPAN: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 108 JAPAN: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 109 JAPAN.: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 110 JAPAN: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 111 JAPAN: RAT MODEL MARKET, BY END USER, 2014–2021 (USD THOUSAND)
Table 112 INDIA: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 113 INDIA: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 114 INDIA: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 115 INDIA: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 116 INDIA: RAT MODEL MARKET, BY END USER, 2014–2021 (USD THOUSAND)
Table 117 REST OF APAC: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 118 REST OF APAC: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 119 REST OF APAC: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 120 REST OF APAC: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 121 REST OF APAC: RAT MODEL MARKET, BY END USER, 2014–2021 (USD THOUSAND)
Table 122 ROW: RAT MODEL MARKET, BY MODEL TYPE, 2014–2021 (USD THOUSAND)
Table 123 ROW: RAT MODEL MARKET, BY SERVICE, 2014–2021 (USD THOUSAND)
Table 124 ROW: RAT MODEL MARKET, BY THERAPEUTIC AREA, 2014–2021 (USD THOUSAND)
Table 125 ROW: RAT MODEL MARKET, BY TECHNOLOGY, 2014–2021 (USD THOUSAND)
Table 126 ROW: RAT MODEL MARKET, BY END USER, 2014–2021 (USD THOUSAND)
Table 127 ROW: RAT CARE PRODUCT MARKET, BY CARE PRODUCT, 2014–2021 (USD THOUSAND)
Table 128 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, 2013–2016
Table 129 ACQUISITIONS, 2013–2016
Table 130 EXPANSIONS, 2013–2016
Table 131 NEW PRODUCT LAUNCHES, 2013–2016
Table 132 OTHER STRATEGIES, 2013–2016
LIST OF FIGURES
Figure 1 GLOBAL RAT MODEL MARKET: RESEARCH METHODOLOGY
Figure 2 SAMPLING FRAME: PRIMARY RESEARCH
Figure 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 4 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 5 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 6 RESEARCH DESIGN
Figure 7 DATA TRIANGULATION METHODOLOGY
Figure 8 GLOBAL RAT MODEL MARKET, BY THERAPEUTIC AREA (2016)
Figure 9 GLOBAL RAT MODEL MARKET, BY MODEL TYPE
Figure 10 GLOBAL RAT MODEL MARKET, BY SERVICE
Figure 11 GLOBAL RAT MODEL MARKET, BY END USER
Figure 12 GLOBAL RAT MODEL MARKET, BY TECHNOLOGY
Figure 13 GLOBAL RAT MODEL MARKET, BY CARE PRODUCT
Figure 14 THE ASIA-PACIFIC RAT MODEL MARKET TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
Figure 15 ATTRACTIVE OPPORTUNITIES IN THE GLOBAL RAT MODEL MARKET
Figure 16 NORTH AMERICA DOMINATED THE GLOBAL RAT CARE PRODUCT MARKET IN 2016
Figure 17 THE TOXICOLOGY SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL RAT MODEL MARKET DURING THE FORECAST PERIOD
Figure 18 THE ASIA-PACIFIC REGION TO WITNESS THE HIGHEST GROWTH IN THE GLOBAL RAT MODEL MARKET FROM 2016 TO 2021
Figure 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
Figure 20 CLINICAL TRIALS USING RAT MODELS, BY INDICATION
Figure 21 CLINICAL TRIALS USING RAT MODELS, BY PHASE
Figure 22 RESEARCH STUDIES USING RAT MODELS, BY INDICATION
Figure 23 BASED ON MODEL TYPE, THE OUTBRED RATS SEGMENT IS ESTIMATED TO DOMINATE THE RAT MODEL MARKET IN 2016
Figure 24 BASED ON SERVICE, THE BREEDING SEGMENT IS ESTIMATED TO DOMINATE THE RAT MODEL MARKET IN 2016
Figure 25 RAT MODEL MARKET, BY TECHNOLOGY, 2016-2021
Figure 26 BASED ON THERAPEUTIC AREA, THE TOXICOLOGY SEGMENT IS ESTIMATED TO DOMINATE THE RAT MODEL MARKET IN 2016
Figure 27 BASED ON END USER, THE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT IS ESTIMATED TO DOMINATE THE RAT MODEL MARKET IN 2016
Figure 28 BASED ON CARE PRODUCT, THE CAGES SEGMENT IS ESTIMATED TO DOMINATE THE RAT CARE PRODUCTS MARKET IN 2016
Figure 29 NORTH AMERICA DOMINATES THE MARKET FOR RAT MODEL PRODUCTS
Figure 30 NORTH AMERICA: RAT MODEL MARKET SNAPSHOT
Figure 31 EUROPE: RAT MODEL MARKET SNAPSHOT
Figure 32 NUMBER OF CELL THERAPY PRECLINICAL STUDIES LISTED IN THE U.K. PRECLINICAL RESEARCH DATABASE, 2013-2016
Figure 33 ASIA-PACIFIC: RAT MODEL MARKET SNAPSHOT
Figure 34 REST OF THE WORLD: RAT MODEL MARKET SNAPSHOT
Figure 35 MAJOR PLAYERS FOCUSING ON INORGANIC GROWTH STRATEGIES
Figure 36 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
Figure 37 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS WAS THE KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS
Figure 38 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, BY COMPANY (2013–2016)
Figure 39 ACQUISITIONS, BY COMPANY (2013–2016)
Figure 40 EXPANSIONS, BY COMPANY (2013–2016)
Figure 41 NEW PRODUCT LAUNCHES, BY COMPANY (2013–2016)
Figure 42 OTHER STRATEGIES, BY COMPANY (2013–2016)
Figure 43 GEOGRAPHIC REVENUE MIX OF TOP MARKET PLAYERS
Figure 44 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT
Figure 45 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
Figure 46 GENOWAY S.A.: COMPANY SNAPSHOT
Figure 47 HORIZON DISCOVERY GROUP PLC: COMPANY SNAPSHOT
Figure 1 GLOBAL RAT MODEL MARKET: RESEARCH METHODOLOGY
Figure 2 SAMPLING FRAME: PRIMARY RESEARCH
Figure 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
Figure 4 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 5 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 6 RESEARCH DESIGN
Figure 7 DATA TRIANGULATION METHODOLOGY
Figure 8 GLOBAL RAT MODEL MARKET, BY THERAPEUTIC AREA (2016)
Figure 9 GLOBAL RAT MODEL MARKET, BY MODEL TYPE
Figure 10 GLOBAL RAT MODEL MARKET, BY SERVICE
Figure 11 GLOBAL RAT MODEL MARKET, BY END USER
Figure 12 GLOBAL RAT MODEL MARKET, BY TECHNOLOGY
Figure 13 GLOBAL RAT MODEL MARKET, BY CARE PRODUCT
Figure 14 THE ASIA-PACIFIC RAT MODEL MARKET TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
Figure 15 ATTRACTIVE OPPORTUNITIES IN THE GLOBAL RAT MODEL MARKET
Figure 16 NORTH AMERICA DOMINATED THE GLOBAL RAT CARE PRODUCT MARKET IN 2016
Figure 17 THE TOXICOLOGY SEGMENT TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL RAT MODEL MARKET DURING THE FORECAST PERIOD
Figure 18 THE ASIA-PACIFIC REGION TO WITNESS THE HIGHEST GROWTH IN THE GLOBAL RAT MODEL MARKET FROM 2016 TO 2021
Figure 19 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
Figure 20 CLINICAL TRIALS USING RAT MODELS, BY INDICATION
Figure 21 CLINICAL TRIALS USING RAT MODELS, BY PHASE
Figure 22 RESEARCH STUDIES USING RAT MODELS, BY INDICATION
Figure 23 BASED ON MODEL TYPE, THE OUTBRED RATS SEGMENT IS ESTIMATED TO DOMINATE THE RAT MODEL MARKET IN 2016
Figure 24 BASED ON SERVICE, THE BREEDING SEGMENT IS ESTIMATED TO DOMINATE THE RAT MODEL MARKET IN 2016
Figure 25 RAT MODEL MARKET, BY TECHNOLOGY, 2016-2021
Figure 26 BASED ON THERAPEUTIC AREA, THE TOXICOLOGY SEGMENT IS ESTIMATED TO DOMINATE THE RAT MODEL MARKET IN 2016
Figure 27 BASED ON END USER, THE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT IS ESTIMATED TO DOMINATE THE RAT MODEL MARKET IN 2016
Figure 28 BASED ON CARE PRODUCT, THE CAGES SEGMENT IS ESTIMATED TO DOMINATE THE RAT CARE PRODUCTS MARKET IN 2016
Figure 29 NORTH AMERICA DOMINATES THE MARKET FOR RAT MODEL PRODUCTS
Figure 30 NORTH AMERICA: RAT MODEL MARKET SNAPSHOT
Figure 31 EUROPE: RAT MODEL MARKET SNAPSHOT
Figure 32 NUMBER OF CELL THERAPY PRECLINICAL STUDIES LISTED IN THE U.K. PRECLINICAL RESEARCH DATABASE, 2013-2016
Figure 33 ASIA-PACIFIC: RAT MODEL MARKET SNAPSHOT
Figure 34 REST OF THE WORLD: RAT MODEL MARKET SNAPSHOT
Figure 35 MAJOR PLAYERS FOCUSING ON INORGANIC GROWTH STRATEGIES
Figure 36 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
Figure 37 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS WAS THE KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS
Figure 38 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS, BY COMPANY (2013–2016)
Figure 39 ACQUISITIONS, BY COMPANY (2013–2016)
Figure 40 EXPANSIONS, BY COMPANY (2013–2016)
Figure 41 NEW PRODUCT LAUNCHES, BY COMPANY (2013–2016)
Figure 42 OTHER STRATEGIES, BY COMPANY (2013–2016)
Figure 43 GEOGRAPHIC REVENUE MIX OF TOP MARKET PLAYERS
Figure 44 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT
Figure 45 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
Figure 46 GENOWAY S.A.: COMPANY SNAPSHOT
Figure 47 HORIZON DISCOVERY GROUP PLC: COMPANY SNAPSHOT
